NOV 10, 2017 05:37 AM PST

Targeting Chromatin Kills Cancer Cells in 3 Days

WRITTEN BY: Xuan Pham
2 47 2125

Image credit: Pixabay.com

By carefully observing how DNA is packaged inside of cancer cells, scientists have developed a therapy that they say can destroy such cells in just three days. The new approach focuses on altering the configuration of the cancer cells’ DNA, and promises future therapy that’s more effective for cancer patients.

While individual genes and mutations often steal the headlines for cancer association, it’s rarely the case that only one gene is involved. "Complex diseases such as cancer do not depend on the behavior of individual genes, but on the complex interplay among tens of thousands of genes,” explained Vadim Backman, co-author and researcher at the McCormick School of Engineering at Northwestern University in Evanston, IL.

As such, Backman and colleagues were interested in a higher level of DNA involvement in cancer. More specifically, they had a hunch that DNA packaging -- how the strands are wrapped, coiled, and condensed inside the nucleus of a cell -- could be cancer’s “Achilles heel.”

"If you think of genetics as hardware," said Backman, "then chromatin is the software." Chromatin is the macromolecule in genetics, comprising of DNA and proteins. Of interest to cancer geneticists, chromatin can regulate gene expression. In its condensed state (heterochromatin), genes are turned off. Conversely, in its relaxed state (euchromatin), DNA is accessible and ready to be expressed. Cancer cells take advantage of these chromatin states for their own survival and proliferation.

The team first devised a way to understand how chromatin behaves in cancer cells. Using a technique called Partial Wave Spectroscopic (PWS) microscopy, they analyzed cancer cells’ chromatin structure in real-time.

In contrast to healthy cells, cancer cells adopted a chromatin “packing density” to help them survive. Moreover, disordered packing density seemed to make these cells more sensitive to chemotherapy. Alas, this was the weakness the team was searching for.

"Just by looking at the cell's chromatin structure, we could predict whether or not it would survive," said Backman. "Cells with normal chromatin structures die because they can't respond; they can't explore their genome in search of resistance. They can't develop resistance."

Next, the team identified drugs that could induce this chromatin vulnerability in cancer cells. Luckily, the drugs that worked for this purpose, Celecoxib and Digoxin, have already been approved by the Food and Drug Administration. In the context of altering the cancer cells’ chromatin packaging, the team referred to these drugs as chromatin protection therapeutics (CPTs).

After treatment with CPTs, cancer cells treated with chemotherapy had a precipitous death toll.

"Within 2 or 3 days, nearly every single cancer cell died because they could not respond. The CPT compounds don't kill the cells; they restructure the chromatin. If you block the cells' ability to evolve and to adapt, that's their Achilles' heel."

While the approach is new and shows remarkable promise, the team is tempered with cautious optimism. "There is a big difference between cell cultures and humans," says Backman. "You never know how the environment inside the human body will affect cancer's behavior or if there will be unforeseen side effects."

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 30, 2018
Infographics
APR 30, 2018
Testicular Cancer Awareness Month - What Do You Know About Testicular Cancer?
In honor of Testicular Cancer Awareness Month, men's underwear brand Tommy John has partnered with the Testicular Cancer Foundation to help those direc
MAY 21, 2018
Cancer
MAY 21, 2018
Malarial Organism Characteristics Leads Researchers To Potential Cancer Therapeutic Target
The malarial parasite expresses a protein, VAR2CSA, that binds to chondroitin sulfate (CS) found on both placental and cancer tissues. Recombinant rVAR2 could be used to target drugs to CS.
MAY 23, 2018
Cell & Molecular Biology
MAY 23, 2018
Understanding Eye Lens Development
As the lens forms during development, its cells have to degrade some of their own parts.
MAY 29, 2018
Health & Medicine
MAY 29, 2018
Skin Cancer Risks for the Military
Another Memorial Day weekend has come and gone, however when most people think of the dangers military service members face, skin cancer and sunburn are no
JUL 03, 2018
Cancer
JUL 03, 2018
Hereditary Myeloid Neoplasm Predisposition
New changes in myeloid classification help to outline a new category of AML which develops as a result of hereditary mutations predisposing family members to myeloid neoplasms in adulthood.
JUL 10, 2018
Cancer
JUL 10, 2018
TdT Positive Cells - Not Just for Neoplasms
TdT positive cells are associated with early lymphoid neoplasms but healthy lymphoid precursors can also be positive, especially in pediatric patient lymph nodes.
Loading Comments...